A follow-up study of hyperechogenicity of the substantia nigra in Parkinson’s disease and atypical parkinsonian syndrome
Objective: To evaluate whether the hyperechogenic size of the substantia nigra changes with time in Parkinson's disease (PD) and atypical parkinsonian syndromes (APSs), such as…Swallowing difficulties and Parkinson’s disease
Objective: To investigate whether swallowing difficulties are associated with presynaptic dopaminergic deficits, distinct clinical phenotypes, CSF biomarkers as well as whether they can predict motor…The effect of expectation on Parkinson’s Disease: an EEG study
Objective: The aim of the present study is to determine how the expectation of receiving a therapeutic treatment influences Parkinson’s disease (PD) symptoms. Background: The…Connectivity patterns in frontal cognitive regions in Parkinson’s disease
Objective: Evaluate the changes in brain connectivity between Parkinson’s disease (PD) with and without mild cognitive impairment (MCI). Background: Up to 40% of PD patients…Hypertension and Parkinson’s disease
Objective: To compared clinical burden, neuropsychological features, CSF and imaging pathology in early untreated PD patients with and without HT. Background: Hypertension (HT) has been…A quantitative meta-analysis study of Impulse control disorders in patients with and without Parkinson’s Disease.
Objective: Evaluating through meta-analysis brain activations associated with impulse control disorder in patients with and without Parkinson ’s disease. Background: Impulse control disorders (ICDs) in…The spectrum of Pantothenate kinase-associated neurodegeneration.A view from seven cases Cohort.
Objective: To describe the clinical spectrum, neurological features and MRI findings of 7 patients, diagnosed as having PKAN. Background: Pantothenate kinase-associated neurodegeneration (PKAN) is an autosomal…Intrathecal Administration of Autologous Mesenchymal Stem Cells in Multiple System Atrophy – A Phase I/II Dose-Escalation Trial
Objective: To explore intrathecal administration of autologous mesenchymal stem cells (MSCs) as therapeutic approach to multiple system atrophy (MSA). Background: MSA is a rapidly progressive…Apomorphine infusion does not impair cognitive action control in Parkinson’s disease
Objective: We sought to verify that apomorphine infusion did not alter cognitive action control.We sought to verify that apomorphine infusion did not alter cognitive action…General Anesthesia and Parkinson’s Disease
Objective: Postoperative cognitive dysfunction is common among the elderly. These changes may even be so severe that some elderly people actually become demented after undergoing…
- « Previous Page
- 1
- …
- 98
- 99
- 100
- 101
- 102
- …
- 155
- Next Page »